About
Approach
Investment Model
Investment Scope
Our approach
Team
Managing Partner
Partners
Our team
Portfolio
News
Connect
Kainova Therapeutics secures $CAD 32 million to accelerate the development of its immuno-oncology and inflammation portfolio.
Article Date
February 10, 2026
This article is featured on another website.
Go to article
Related posts
Browse all articles
August 13, 2026
The Oligodendrocyte Advantage
August 13, 2026
The Oligodendrocyte Advantage
August 14, 2026
From Bioprocessing to the Digital Age: Chime Biologics at the Bioprocessing Summit 2026
August 14, 2026
From Bioprocessing to the Digital Age: Chime Biologics at the Bioprocessing Summit 2026
